Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) Shares Outstanding (Diluted Average) (2021 - 2026)

Design Therapeutics' Shares Outstanding (Diluted Average) history spans 1 years, with the latest figure at $45.9 million for Q4 2021.

  • On a quarterly basis, Shares Outstanding (Diluted Average) changed N/A to $45.9 million in Q4 2021 year-over-year; TTM through Dec 2021 was $45.9 million, a N/A change, with the full-year FY2021 number at $45.9 million, changed N/A from a year prior.
  • Shares Outstanding (Diluted Average) hit $45.9 million in Q4 2021 for Design Therapeutics, down from $55.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for DSGN hit a ceiling of $55.2 million in Q3 2021 and a floor of $36.5 million in Q2 2021.